Kidney Cancer Weekly

June 15, 2026

Videos

Peer-to-Peer Clinical Conversations

KEYMAKER-U03 Substudy Compares Four Combinations to Standard Therapy - Cristina Suárez

Cristina Suárez

Pedro Barata speaks with Cristina Suárez about KEYMAKER-U03 substudy 03A results evaluating checkpoint combinations in first-line metastatic clear cell renal cell carcinoma.

COSMIC-313 Correlative Analysis Links Specific T-Cell Subset to Improved PFS with Immunotherapy - Berkay Simsek

Pedro Barata hosts Berkay Simsek to discuss correlative biomarker analysis from the COSMIC-313 trial examining immune cell populations in patients receiving ipilimumab plus nivolumab for advanced clear cell renal cell carcinoma.

Beyond the Abstracts

Pattern of Disease Recurrence and Outcomes after Progression of High-Risk Renal Cell Carcinoma (RCC) Patients Treated with Adjuvant Immunotherapy - Beyond the Abstract

Partitioned Overall Survival: Comprehensive Analysis of Survival States over 4 Years in CheckMate 9ER Comparing First-Line Nivolumab plus Cabozantinib versus Sunitinib in Advanced Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

ASCO 2026: Ultrasensitive ctDNA Detection and Molecular Clearance as a Prognostic and Predictive Marker in Advanced RCC

ASCO 2026: PEAK-1: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell RCC

AUA 2026: Comparison between IO–IO and IO–TKI Combination Therapies for Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

AUA 2026: State-of-the-Art Lecture: The Emerging Role of Focal Therapy in Renal Cell Carcinoma

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Iceball Margin ted with Local Failure after CT-guided Cryoablation of cT1a Renal Cell Carcinoma

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.

Feasibility and Safety of a Ketogenic Diet During Systemic Therapy for Metastatic Renal Cell Carcinoma: Results from the Cetorein Pilot Study.

Case Report: donor cell-derived leukemia after allogeneic stem cell transplantation for metastatic renal cell carcinoma.

Clinicopathologic features and survival disparities in early onset clear cell renal cell carcinoma in Texas.

Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III Renal Cell Carcinoma.

Comparison of partial nephrectomy to radical nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian Multi-Institutional Collaborative.

Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney Cancer.

ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinoma.

Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time-Varying Effects.

Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC